The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.